| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 1, Issue 2 63-71, Copyright © 1990 by American Association of Cancer Research
ARTICLES |
A Wellstein, R Lupu, G Zugmaier, SL Flamm, AL Cheville, P Delli Bovi, C Basilico, ME Lippman and FG Kern
Medicine Branch, NCI, National Institutes of Health, Bethesda, Maryland 20892.
We studied the different potentials of a secreted and a nonsecreted member of the fibroblast growth factor (FGF) family to induce autocrine growth stimulation in human adrenal cortex carcinoma cells (SW-13). These epithelial cells express basic FGF (bFGF) cell surface receptors, and picomolar concentrations of bFGF suffice to induce anchorage-independent growth. The requirement for exogenously added bFGF contrasts with the intracellular storage of biologically active bFGF in SW-13 cells greater than 10,000-fold in excess of the concentration needed to stimulate anchorage independent growth. To study whether the expression of a secreted FGF would alter the growth phenotype of these cells, we transfected them with an expression vector coding for the Kaposi-fgf (K-fgf) oncogene. In contrast to controls, K-fgf-transfected cells secrete significant amounts of biologically active K-fgf protein into the growth media, show up to 50-fold increased colony formation in soft agar, and grow into rapidly progressing, highly vascularized tumors in athymic nude mice. A reversible inhibition of the autocrine growth stimulation in vitro is brought about by the polyanionic compound suramin. We conclude that FGF has to be released from SW-13 cells to function fully as a growth stimulator in vitro and in vivo.
This article has been cited by other articles:
![]() |
G. E. Stoica, A. Kuo, C. Powers, E. T. Bowden, E. B. Sale, A. T. Riegel, and A. Wellstein Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types J. Biol. Chem., September 20, 2002; 277(39): 35990 - 35998. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Weber, H.-J. Klomp, F. Czubayko, A. Wellstein, and H. Juhl Pleiotrophin Can Be Rate-limiting for Pancreatic Cancer Cell Growth Cancer Res., September 1, 2000; 60(18): 5284 - 5288. [Abstract] [Full Text] |
||||
![]() |
Z. He and A. Bateman Progranulin Gene Expression Regulates Epithelial Cell Growth and Promotes Tumor Growth in Vivo Cancer Res., July 1, 1999; 59(13): 3222 - 3229. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Souttou, S. Ahmad, A. T. Riegel, and A. Wellstein Signal Transduction Pathways Involved in the Mitogenic Activity of Pleiotrophin. IMPLICATION OF MITOGEN-ACTIVATED PROTEIN KINASE AND PHOSPHOINOSITIDE 3-KINASE PATHWAYS J. Biol. Chem., August 1, 1997; 272(31): 19588 - 19593. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |